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Expression of transforming growth factor-a isoforms in human gb-
merular diseases. Protein and mRNA expression of TGF-f3 isoforms,
TGF-/31, -/32 and -f33, and deposition of fibronectin containing extra
domain A (fibronectin EDA+) and plasminogen activator inhibitor-i
(PAT-i) were studied in human chronic glomerulonephritis and diabetic
nephropathy. Normal kidneys showed similar, weak immunostaining for
all three TGF-/3 isoforms. TGF-f3 mRNA expression was weak for all
isoforms with TGF-J3i>TGF-(33>TGF-/32. tn thin basement membrane
disease and minimal change disease, disorders where extracellular matrix
accumulation is not a feature, immunoreactivity and mRNA expression
did not differ from normal. In contrast, diseases characterized by extra-
cellular matrix accumulation (IgA nephropathy, focal and segmental
glomerulosclerosis, crescentic glomerulonephritis, lupus nephritis and
diabetic nephropathy) all showed significantly increased expression of the
three TGF-J3 isoforms in gbomeruli and the tubulointerstitium. While
glomerular and tubulointerstitial deposition of two matrix components
induced by TGF-f3, fibronectin EDA+ and PAl-i, was significantly
elevated in all diseases with matrix accumulation, correlation analysis
revealed a close relationship primarily with TGF-/31. We conclude that,
for a spectrum of human glomerular disorders, increased protein expres-
sion of all three TGF-/3 isoforms and proteins induced by TGF-/3 is
associated with pathological accumulation of extracellular matrix.
Although progressive renal diseases such as chronic glomeru-
lonephritis and diabetic nephropathy have different etiologies, the
histological changes in the kidney are characterized ultimately by
glomerulosclerosis and tubular atrophy with interstitial fibrosis
resulting from excessive accumulation of extracellular matrix.
These similar pathological features suggest that a common patho-
genic factor for scarring may be operating [1—3]. Recent work
supports the hypothesis that overexpression of transforming
growth factor-/3 (TGF-/3) is this common pathogenic factor. The
original observation in the anti-thymocyte model of acute mesan-
gioproliferative glomerulonephritis, that TOF-/3 overproduction
is the cause of fibrosis [4, 5], has been confirmed in a number of
other models of kidney disease. The evidence that TGF-13 plays a
causative role in fibrotic disorders of many organs has recently
been reviewed [6] and continues to increase [7]. This body of work
predicts that there would be overexpression of TGF-f3 in human
renal disorders characterized by pathologic accumulation of ex-
tracellular matrix. The study reported here was undertaken, in
part, to test this hypothesis.
In mammals, three isoforms of TGF-f3, TGF-/31, -/32 and -/33
have been identified. They are synthesized as large prepropro-
teins, of which the biologically active TGF-/3s reside in the
carboxy-terminus. Although their amino-terminal precursor se-
quences are dissimilar, the carhoxy-terminal 112 amino acids of
the mature TGF-f3 peptides exhibit 70 to 75% conservation of
amino acid sequence and 100% conservation of the nine cystine
residues [8]. The TGF-f3 isoforms possess qualitatively similar
actions on cells in vifro [9], but their spatial and temporal
expression differs in embryogenesis [30—12], regenerating tissues
[13—15] and in fibrotic disorders [6, 7].
It is known that in diseased glomeruli, TGF-f3 facilitates matrix
accumulation in at least three ways by inducing (1) increased
synthesis of matrix proteins [16, 17], (2) increased synthesis of
integrins involved in matrix assembly at the cell surface [18], and
(3) increased synthesis and matrix deposition of protease inhibi-
tors, thereby decreasing matrix degradation [19, 20]. Neutraliza-
tion of TGF-j3 activity by injection of either antibodies or the
proteoglycan decorin ameliorates the effect of this growth factor
[21, 22]. Across a spectrum of human renal disorders, we have
examined extraeellular deposition of fibronectin EDA+ and
plasminogen activator inhibitor-i (PAT-i), components which are
induced by TGF-/3 and are part of two of these processes.
Fibronectin EDA+, an isoform containing a spliced mRNA
variant termed extra domain A, is found in healing wounds where
it may act to facilitate matrix assembly, and is a sensitive marker
of TGF-/3's fibrogenic actions [23—25]. PAT-i is rapidly up-
regulated by TUE-p and is thought to decrease matrix degrada-
tion by inhibiting generation of the matrix degrading protease,
plasmin [26—29].
Multiple regression analysis was adopted to study the correla-
tion between the level of each TGF-/3 isoform and that of each
matrix protein in glomeruli and the tubulointerstitium.
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Methods
Kidney samples
Needle biopsy specimens of human kidney tissue remaining
after diagnostic evaluation were obtained from Cedars-Sinai
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Medical Center, Los Angeles, California, USA, and Hamamatsu
University Hospital, Hamamatsu, Japan. The patients were diag-
nosed prior to our study according to standard criteria [30].
Biopsy tissue from fifty-three patients included the following
distribution of disease: thin basement membrane disease (5),
minimal change disease (7), IgA nephropathy (13), focal and
segmental glomerulosclerosis (5), immune complex-mediated
crescentic glomerulonephritis (5), focal proliferative lupus nephri-
tis (6), diffuse proliferative lupus nephritis (7), and diabetic
nephropathy (5). Seven normal kidney samples were used as
control tissues. All samples included at least five glomeruli.
Antibodies 0
Antibodies to the three isoforms of TGF-/3 were prepared by
immunizing rabbits with synthetic peptides of each isoform as
described elsewhere [Ii]. Peptides of amino acid residues 4 to 19
were used to raise TGF-/31 and /32 antibodies and residues 9 to 20
were used for TGF-/33. The antibodies were purified by affinity
chromatography using the respective immunogen peptides. West-
ern blot analysis demonstrated that each purified antibody reacted
only with the active, but not latent, form of the appropriate
TGF-/3 isoform [11].
Mouse monoclonal antibody to human fibronectin EDA+ and
human PAl-i were obtained from Accurate Chemical and Scien-
tific Corporation (Westbury, NY, USA) [23] and American Diag-
nostica, Inc. (Greenwich, CT, USA), respectively. Fluorescein
isothiocyanate (FITC)-conjugated donkey F(ab')2 anti-rabbit an-
tibody and FITC-conjugated rat F(ab')2 anti-mouse IgG antibody
were used as secondary antibodies (Jackson Immunoresearch,
West Grove, PA, USA).
Immunohistological examination
Serial cryostat sections (4 tm) were fixed in acetone, washed in
0.15 M phosphate buffered saline, pH 7.4 (PBS), incubated with
the primary antibodies, washed with PBS, incubated with the
appropriate FITC-conjugated secondary antibodies, washed again
and mounted with cover glasses using Bartels buffered glycerol
mounting medium FA (Baxter, Deerfield, IL, USA).
The intensity of glomerular staining of TGF-/31, TGF-/32,
TGF-p3, fibronectin EDA+ and PAl-i was evaluated according
to the following 0 to 4 scale in coded sections observed at 400x
magnification: 0 = nostaining; I = weak and spotty intraglomeru-
lar staining; 2 = moderate and segmental intraglomerular stain-
ing; 3 = moderately strong and segmental, or moderate but diffuse
(involving more than 50%) intraglomerular staining; and 4 =
strong and diffuse intraglomerular staining. The intensity of
tubulointerstitial staining in cortical areas was evaluated accord-
ing to the following 0 to 4 scale in the coded sections observed at
250x magnification: 0 = no staining; I = deposition that involves
less than 10% of the cortical area; 2 = involving 10 to 30%; 3 =
involving 30 to 50%; and 4 = involving more than 50%. All, or at
least five glomeruli and twenty randomly selected cortical tubu-
lointerstitial areas per sample were evaluated. The mean values of
the glomerular and tubulointerstitial scores were calculated.
In situ hybridization
In situ hybridization to examine the expression of TGF-/31, -/32
and -/33 mRNAs was performed on fifteen samples including one
sample of normal kidney, three of minimal change disease, six of
IgA nephropathy, two of crescentic glomerulonephritis, one of
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Fig. 1. Giomerular (A) and tubulointerstitial (B) immunofluorescence stain-
ing scores of TGF-pI •), TGF-/32 () and TGF-/33 (LII) in normal control
(NC), thin basement membrane disease (TBMD), minimal change disease
(MCD), IgA nephropathy (IgA), focal and segmental glomerulosclerosis
(FGS), crescentic glomerulonephritis (CresGN), focal proliferative lupus
nephritis (FPLN, diffuse proliferative lupus nephritis (DPLN) and diabetic
nephropathy (DN). The error bars represent SE. *P < 0.025 versus normal
control.
focal proliferative lupus nephritis and two of diffuse proliferative
lupus nephritis.
Four-micrometer serial sections of 4% paraformaldehyde-fixed,
paraffin-embedded renal tissues were placed on 3-aminopropyl-
triethoxysilane-coated slides. The cDNA plasmids of murine
TGF-j31, pmTGF-/31-A, murine TGF-f32, pmTGF-/32 to 9A, and
murine TGF-/33, pmTGF-133 to lib were kindly provided by Dr.
H.L. Moses (Vanderbilt University, Nashville, TN, USA) [31, 32].
Antisense and sense cRNA riboprobes were generated after
digestion with restriction enzymes (Takara Shuzo, Otsu, Japan),
HindIII and EcoRl for TGF-/31, EcoRI and XhoI for TGF-f32,
and Hindill and XhoI for TGF-/33, respectively. Riboprobes were
labeled with digoxigenin using the DIG RNA labeling kit (Boehr-
inger Mannheim Biochemica, Mannheim, Germany). Sections
were rehydrated, digested with 10 g/ml of proteinase K (Boehr-
inger Mannheim) for 15 minutes at 37°C, post-fixed in 4%
paraformaldehyde, treated with 0.2 N HCI, acetylated in 0.1 M
triethanolamine and 0.25% acetic anhydride. Digoxigenin-labeled
riboprobes were added to the hybridization solution containing
50% deionized formamide, 0.3 M NaCI, 10 mrvi Tris HC1, pH 8.0,
5 mM EDTA, 10 mrvi NaH2PO4, 0.2 mglml salmon sperm DNA
(Sigma, St. Louis, MO, USA), 0.1 mglml yeast transfer RNA
(Takara), 1 >< Denhardt's solution, and 10% dextran sulfate.
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Fig. 2. Immunofluorescence micrographs of TGF- j31 (a, d), TGF-132 (b, e) and TGF-J33 (c, V in the serial sections of normal control (a, b, c) and crescentic
glomerulonephritis (d, e, f). Compared with normal control, diffuse and strong intraglomerular staining of the three TGF-13 isoforms was observed in
crescentic glomerulonephritis. The Bowman's capsules forming crescents and the periglomerular interstitial lesions showed strong staining of the three
TGF-13 isoforms. Some tubules in the vicinity of interstitial mononuclear cell infiltration were also positive for the three TGF-f3 isoforms. (magnification
x230).
Hybridization was performed with 10 nglml of digoxigenin-labeled
riboprobe added to each slide and incubated for 18 hours at 50°C.
The slides were washed sequentially with 5 X SSC, and 2 X SSC
containing 50% formamide at 50°C and treated with 20 g/ml of
RNase A (Boehringer Mannheim) for 30 minutes at 37°C. Wash-
ing was then continued once with 2 x SSC and twice with 0.2 X
SSC at 50°C. Slides were washed with buffer 1(0.1 M Tris-HC1 and
0.15 M NaCI, pH 7.5) and incubated with buffer 1 containing 10%
normal sheep serum and 1.5% blocking reagent (Boehringer
Mannheim) for 60 minutes at room temperature. The sections
were incubated with alkaline phosphatase-conjugated sheep anti-
digoxigenin antibody (Boehringer Mannheim) diluted 1:500 in
buffer 1 containing 1% normal sheep serum for 60 minutes at
room temperature. The slides were washed twice with buffer I and
rinsed in buffer 3 (0.1 M Tris HCI, 0.1 M NaCI, 0.05 M MgCI2, pH
9.5), The color solution was added which consisted of 45 tl 4-nitro
blue tetrazolium chloride (NBT), 35 p1 5-bromo-4-chloro-3-in-
doylphosphate (Boehringer Mannheim) and 2.5 mg levamisole
(Sigma) in 10 ml buffer 3. The color reaction was developed in a
dark-box and stopped with 0.01 M Tris-HC1, 1 mivi EDTA, pH 8.0.
Slides were rinsed in distilled water and covered with aqueous
mounting medium.
Statistical analysis
Differences between groups in immunofluorescence scoring of
TGF-p isoforms and matrix components were analyzed by the
Student's 1-test. Correlations between the staining intensity of
each TGF-/3 isoform and that of fibronectin EDA+ and PAL-I in
the glomeruli and the tubulointerstitium were analyzed using
multiple regression analysis.
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cellular and associated with the matrix in the glomeruli and the
tubulointerstitium. Diffuse and strong intraglomerular staining of
the three TGF-13 isoforms was found in diffuse proliferative lupus
nephritis, crescentic glomerulonephritis (Fig. 2) and diabetic
nephropathy, while segmental intraglomerular staining was ob-
served in IgA nephropathy, focal and segmental glomerulosclero-
sis and focal proliferative lupus nephritis. The Bowman's capsules,
crescents, and the periglomerular and tubulointerstitial lesions
with interstitial mononuclear cell infiltration and matrix deposi-
tion showed remarkably strong immunostaining of the three
TGF-/3 isoforms (Fig. 2). Some tubules surrounded by interstitial
mononuclear cells and the interstitial arteries with intimal thick-
ening were also positively stained.
Deposition of fibronectin EDA + and PAl-i
In normal kidneys, trace deposits of fibronectin EDA+ and
PAl-i were observed in glomeruli and the interstitium (Figs. 3 and
4). Similar immunostaining was seen in minimal change disease
and thin basement membrane disease (Fig. 3).
In IgA nephropathy, focal and segmental glomerulosclerosis,
crescentic glomerulonephritis, lupus nephritis and diabetic ne-
phropathy, significantly increased deposition of fibronectin
EDA+ and PAl-i was noted in glomeruli showing mesangial
matrix accumulation, in the crescents, and in the periglomerular
and tubulointerstitial lesions where mononuclear cell infiltration
and increased interstitial matrix deposition were observed (Figs. 3
and 4).
In situ hybridization for detection of TGF-f3 isoform mRJ'JA
In normal kidney, weak expression of TGF-/31 mRNA was
observed in a few glomerular cells. Some Bowman's capsular
epithelial cells, distal tubules, interstitial arteries and a few
interstitial cells were also weakly positive for TGF-f31 mRNA
expression. The expression of TGF-f33 mRNA was similar to, but
slightly weaker than that of TGF-/31 mRNA. The glomerular and
tubulointerstitial expression of TGF-f32 mRNA was much weaker
than that of TGF-/31 and -133 mRNA. Compared with normal
control tissues, no remarkable differences in the levels of mRNA
expression of the three TGF-13 isoforms were found in the
glomeruli and the tubulointerstitium in minimal change disease
(Figs. 5 A, B and C).
In IgA nephropathy, increased mRNA expression for each of
the three TGF-J3 isoforms was found in a few intraglomerular cells
in proliferative lesions, glomerular epithelial cells in the glomer-
ular tufts adhering to Bowman's capsules, Bowman's capsular
epithelial cells, and periglomerular interstitial mononuclear cells
(Figs. 5 D, E and F). Although proliferating glomerular cells were
mainly mesangial cells, it is possible that some glomerular epithe-
hal cells, monocyte/macrophages and endothelial cells also ex-
press TGF-/3. Increased expression of mRNA for the three TGF-13
isoforms was also observed in the glomerular and tubulointersti-
tial lesions in lupus nephritis (Figs. 5 G, H and I). The intensity of
TGF-13 mRNA expression of all three isoforms in glomerular and
tubulointerstitial cells was greater in diffuse proliferative lupus
nephritis than in focal proliferative lupus nephritis. In crescentic
glomerulonephritis, diffuse proliferative lupus nephritis and se-
verely proliferative IgA nephropathy, remarkably strong expres-
sion of mRNA for the three isoforms was noted in crescent cells,
0
Fig. 3. Glomerular (A) and tubulointerstitial (B) immunofluorescence stain-
ing scores of fibronectin EDA + ) and PAl-i () in normal control (NC),
thin basement membrane disease (TBMD), minimal change disease (MCD),
IgA nephropathy (IgA), focal and segmental glomerulosclerosis (FGS),
crescentic glomerulonephritis (CresGN), focal proliferative lupus nephritis
(FPLN), diffuse proliferative lupus nephritis (DPLN) and diabetic nephrop-
athy (DN). The error bars represent SE. *P < 0.01 versus normal control.
Results
Immunohistological staining of TGF-/31, -132 and -133 isoforms
In normal kidneys, slight immunoreactivity for the three TGF-J3
isoforms were observed in glomeruhi and in interlobular arteries
(Figs. 1 and 2). In glomerular diseases that do not show excessive
matrix accumulation, minimal change disease and thin basement
membrane disease, glomerular and tubulointerstitial immunos-
taming of the three TGF-p isoforms was similar to that of normal
kidneys (Fig. 1).
In disorders with abnormal glomerular and tubulointerstitial
matrix accumulation, including IgA nephropathy, focal and seg-
mental glomerulosclerosis, crescentic glomerulonephritis, diffuse
proliferative lupus nephritis and diabetic nephropathy, significant
increases in the immunoreactivity of all three TGF-f3 isoforms
were noted in glomeruli (P < 0.025) and tubulointerstitium (P <
0.025; Fig. 1). Although significant increases in isoform staining
were also found in glomeruli from patients with focal proliferative
lupus nephritis and IgA nephropathy (P < 0.025), lesions with
similar morphological changes, the staining intensity was less than
that in glomeruli from patients with diffuse proliferative lupus
nephritis (P < 0.05). No significant differences were noted in
tubulointerstitial staining of focal proliferative lupus nephritis
(Fig. 1).
Immunoreactivity for all three TGF-f3 isoforms was both intra-
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Fig. 4. Immunofluorescence micrographs of fibronectin EDA + (a, c) and PAl-i (b, d) in serial sections of normal control (a, b) and crescentic
glomenilonephritis (c, d). Remarkably strong intraglomerular and tubulointerstitial staining of fibronectin EDA+ and PAl-i was found in crescentic
glomerulonephritis. (magnification X270).
periglomerular mononuclear cells around the crescents, and in-
terstitial mononuclear cells in the tubulointerstitial lesions show-
ing increased matrix deposition (Figs. 5 G, H and I). Proximal and
distal tubules surrounded by interstitial mononuclear cells were
also positive for all three isoforms. Labeling of the control sense
probes was not increased over background (results not shown).
Correlation between each TGF-j3 isoform and fibronectin EDA +
and PAL]
To determine whether expression of each isoform was equally
related to the markers of matrix accumulation, fibronectin EDA+
and PAl-i, multiple regression analysis was performed. The
results presented in Table 1 indicate that the levels of glomerular
and tubulointerstitial deposition of fibronectin EDA+ were cor-
related only with TGF-J31 immunostaining and PAT-i staining was
correlated with that of TGF-131 and TGF-133 but not TGF-132.
Discussion
The data presented demonstrate that, as previous studies of
animal models would predict, TGF-13 protein and mRNA expres-
sion are markedly increased in human glomerular disorders
characterized by extracellular matrix accumulation. Moreover, the
increased immunoreactivity for fibronectin EDA+ and PAl-I
strongly suggests that TGF-/3 is acting to increase matrix accumu-
lation. These results confirm and expand a previous study from
this laboratory on experimental and human diabetic nephropathy
[5] and work by Yoshioka et al [33] where, in human mesangio-
proliferative glomerulonephritis, increases in TGF-pl protein and
mRNA were shown to be closely correlated to the degree of
mesangial matrix expansion.
Although the effects of the three TGF-13 isoforms on matrix
production are usually similar when added to cells in vitro [9],
TGF-/31 is generally considered to be the "fibrogenic" cytokine in
vivo. Intravenous or intraperitoneal injection of TGF-131 leads to
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Fig. 5. In situ hybridization demonstrating the expression of TGF-131 mRNA (a, d, g), TGF-f32 mRNA (b, e, h) and TGF-133 mRNA (c, f, I) in serial sections
of minimal change disease (a, b, c), IgA nephropathy with mild mesangialproliferation (d, e, f) and diffuse proliferative lupus nephritis with crescent form ation
(g, h, i). In minimal change disease, weak expression of the three TGF-13 isoforms' mRNA was observed in a few glomerular cells, Bowman's capsular
epithelial cells and interstitial cells. The expression of TGF-132 mRNA was weaker than that of TGF-/31 and -133 mRNA. In IgA nephropathy with mild
mesangial proliferation, mild increases in the expression of the three TGF-/3 isoforms were found in some intraglomerular cells, Bowman's capsular
cpithelial cells and interstitial mononuclear cells. In the IgA case shown here, the expression of TGF-/32 mRNA was weaker than that of TGF-/31 and
/33 mRNA. In diffuse proliferative lupus nephritis with crescent formation, increased expression of mRNA for all three TGF-13 isoforms was observed
in the glomerular and tubulointerstitial lesions. Remarkably strong TGF-/3 isoform expression was noted in the intraglomerular cells near Bowman's
capsular adhesions, the capsular cells forming crescents, the periglomerular mononuclear cells around the crescents, and the interstitial mononuclear
cells in the tubulointerstitial lesions. Proximal and distal tubular cells surrounded by interstitial mononuclear cells were also positive. In the case shown
here, the expression of TGF-/33 mRNA was less than that of TGF-f31 and /32 mRNA. Relatively strong expression of TGF-32 mRNA was observed in
the proximal tubular cells seen on the lower left of each Figure (magnification X 140).
Table 1. Multiple regression analysis of the correlation between the levels of each TGF-f3 isoform and those of fibronectin EDA+ and PAl-i in
the glomerulus and the tubulointerstitium in chronic glomerulonephritis
Fibronectin EDA+' PAI-r'
Glomerulus Tubulointerstitium Glomerulus Tubulointerstitium
Coefficient P valueVariable name Coefficient P value Coefficient P value Coefficient P value
TGF-/31
TGF-/32
TGF-/33
0.52
0.08
0.16
0.006
0.734
0.536
0.59
—0.18
0.39
0.009
0.362
0.078
0.31
0.13
0.53
0.032
0.463
0.011
0.38
—0.01
0.51
0.037
0.968
0.006
a Dependent variable
generalized tissue fibrosis [34, 351 TGF-f31 gene transfer into the
mesangium of normal rats by injection into the renal artery
rapidly leads to glomerulosclerosis [361. In a transgenic mouse
model in which the TGF-f31 gene was linked to the albumin
promoter so that TGF-f31 would be produced in the liver, elevated
plasma levels of TGF-/31 induced glomeruloscierosis and renal
failure in some lines [37]. TGF-f31 has been shown to be up-
regulated in virtually all experimental models of fibrotic disease
and in human diseases where it has been studied [6, 7]. Thus, the
evidence supporting TGF-/31 's fibrogenic actions is considerable.
In general, however, these studies have not explored the roles of
-132 and -/33 in fibrogenesis. Studies of TGF-/3 isoform mRNA and
immunoreactivity during normal mouse development [11, 12],
immunoreactivity during repair in regenerating liver [15], and in
excisional wound repair [14, 15] have shown spatial and temporal
differences in isoform expression. We have recently reported
TGF-/3 isoform staining data in acute and chronic kidney trans-
plant rejection [38]. In chronic rejection, the results of staining
were similar to those reported here: significantly increased tubu-
lointerstitial and glomerular staining for all three TGF-/3 iso-
forms, as well as for fibronectiri EDA+ and PAl-i [38]. Significant
increases in expression of all three TGF-f3 isoforms were also seen
in two models of acute, reversible fibrosis in the rat, including
pulmonary fibrosis induced by bleomycin [391 and glomerulone-
phritis induced by anti-thymocyte serum (unpublished data).
However, in fibrotic liver disease, when expression of TGF-f31 and
-f32 was examined by in situ hybridization, an elevation of TGF-/31
mRNA was seen in most cell types with the exception of hepato-
cytes [40]. TGF-/32 mRNA was elevated only in bile duct epithe-
hal cells [40]. Data on human progressive systemic sclerosis
suggest that, in the skin, TGF-/32 is elevated more than TGF-/31
[41—43]. Therefore, it appears that overexpression of TGF-/3
isoforms may occur in different patterns in different tissues and
during acute injury compared to chronic fibrosis. Additional
studies are clearly needed.
The work presented here is the first study of human chronic
fibrotic diseases where both mRNA and isoform staining have
been investigated. The data show a strong correlation between
TGF-f31 expression and the deposition of matrix proteins, thus
confirming the role of TGF-f31 in fibrotic diseases of the kidney.
Our results also demonstrate that TGF-/32 and -133 isoform
production is elevated, raising the question of whether TGF-J32
and -/33 have specific roles in chronic fibrosis or whether their
actions are entirely overlapping with those of TGF-p1. The use of
agents such as antibodies that neutralize specific isoforms will
help to answer this question.
Little is known of the mechanism of up-regulation of TGF-l3
expression and the factors or conditions that maintain its overex-
pression during chronic fibrosis. It is clear from work in vitro that,
depending on cell type, there is autoregulation and cross-regula-
tion of TGF-/3 isoforms [44]. The mechanism of these autoinduc-
tion loops is known only for TGF-/31 [45].
An interesting feature of the findings reported here, as well as
those found in chronic kidney transplant rejection [38], is that
despite considerable fibrosis and cell death, the viable cells within
these tissues retain the ability to overexpress TGF-J3. Although
fibronectin EDA+ and PAl-i mRNA levels were not measured,
the increased immunoreactivity for these proteins suggest that
overexpression of TGF-/31 leads to continued matrix protein
synthesis and deposition and continued inhibition of matrix
degradation, thus allowing fibrosis to advance. Our data are
consistent with those of Peten et al [46], who found, by rtPCR of
mRNA from microdissected glomeruhi, that a2IV collagen
mRNA remained many-fold elevated above normal even in
glomeruli of patients with advanced glomerulosclerosis.
468 Yamamoto et al: TGF-j3 isoforms in glomerular disease
The data presented support the hypothesis that overexpression
of TGF-f3 underlies tissue fibrosis in chronic disease, and indicate
that expression of all three isoforms is increased in a manner
consistent with the severity of disease. Finally, these data provide
the exciting suggestion that therapeutic intervention directed
toward blocking TGF-f3 may be effective even in advanced
disease.
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